ArticleTranslational vision science & technology2025
Advancing Toward a World Without Vision Loss From Diabetes: Insights From The Mary Tyler Moore Vision Initiative Symposium 2024 on Curing Vision Loss From Diabetes.
Article in Translational vision science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The Mary Tyler Moore Vision Initiative (MTM Vision) honors Mary Tyler Moore's commitment to ending vision loss from diabetes. Founded by Moore's husband, Dr. S. Robert Levine, MTM Vision aims to accelerate breakthroughs in diabetic retinal disease (DRD). At the MTM Vision Symposium 2024 on Curing Vision Loss from Diabetes, experts highlighted the urgent need for updated DRD staging systems, clinically relevant endpoints, and novel biomarkers to detect early disease changes. MTM Vision is advancing two clinical trials in collaboration with the DRCR Retina Network, launching a public awareness campaign, and welcoming Boehringer Ingelheim as the first founding industry member of its pre-competitive Consortium. Speakers emphasized big-data strategies and artificial intelligence (AI)-driven tools to improve DRD diagnosis, risk prediction, and personalized treatment. They also showcased new efforts to bridge academic discoveries with industry expertise, illustrating promising work on vascular regeneration and cellular senescence that may yield future therapies. The MTM Vision Biorepository and Resource Center is expanding tissue collections, enabling multi-omics analyses to study DRD mechanisms. Patient voices were central to the discussion, with calls for enhanced patient-reported outcomes, caregiver support, and broader education on DRD's risks. The symposium also underscored the importance of integrating mental health, quality of life measures, and ongoing patient input to guide clinical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.